Au revoir, Sanofi: John Reed dashes to J&J; Zentalis plucks new COO from GSK
→ Something big had to be brewing when Sanofi announced the departure of R&D chief John Reed bright and early Monday morning. Is he taking a CEO job? Or some other high-profile gig? Fourteen hours later, we learned that his next Big Pharma challenge awaits.
Reed will technically replace Mathai Mammen as EVP of pharmaceuticals, R&D at J&J on April 3, but William Hait had been pinch-hitting in this position after Mammen’s sudden exit last August. Patent cliffs have hit the pharma giant with Remicade and Zytiga, and J&J is bracing for the impact created by Stelara’s loss of exclusivity, but newer approvals like the BCMA bispecific Tecvayli and the BCMA CAR-T Carvykti will try to cushion the blow. Reed will have a battle on his hands, though, with Bristol Myers Squibb’s Abecma in the multiple myeloma CAR-T space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
